Clinical Trial Detail
Home > Clinical Trial Detail
Detail Information Last Updated: 29-Apr-2025
Identifier No. : eCTS-2025-068


Certificate Holder : Parexel International (Hong Kong) Company Limited
Protocol Title : A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy or in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors
Protocol No. : ALE.P02.01
Trial Drug : ALE.P02 Inj.


Initial Certificate Issuance Date Trial Site Principal Investigator
29-Apr-2025 Prince of Wales Hospital (including Phase I Clinical Trial Centre, The Chinese University of Hong Kong) Dr. MA, BUIG YUE BRIGETTE